MuControl-Sum: A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis

Sponsor
Ad scientiam (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06132048
Collaborator
(none)
17
1
1
6
2.8

Study Details

Study Description

Brief Summary

The study aims to assess the usability and safety of use of MuCopilot, a smartphone application that measures objective data on lung function, global exercise capacity and patient reported outcomes of patients with Cystic Fibrosis (CF). These data are collected during unsupervised digital tests performed in the patient's home environment between consultations.

The primary objective is to validate the usability and safety of use, in order to assure that the patients use the medical device as intended without any unacceptable error of use and without unacceptable risk.

The study will include 17 CF patients and will be conducted in France. They will participate in 1 inclusion visit and 1 visit in-clinic (1h30).

Patients will be able to download the free MuCopilot mobile application. During the visit, patients will complete 3 digital tests in order to monitor CF functions (cough, dyspnea & walking) and 1 symptom questionnaire.

Condition or Disease Intervention/Treatment Phase
  • Device: MuCopilot mobile application
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
17 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
Anticipated Study Start Date :
Apr 1, 2024
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: MuCopilot - Summative evaluation

Performance of digital tests and questionnaire from MuCopilot, during the visit.

Device: MuCopilot mobile application
MuCopilot is a software as medical device with three digital tests, to measure patient's with CF, lung function, global exercise capacity and a questionnaire to address CF symptoms and impacts on some aspects of patient's life

Outcome Measures

Primary Outcome Measures

  1. Validation of usability (1) [2 hours]

    Use error : Any deviation from the instructions for use that does not result in a response from the medical device other than what the manufacturer intended. Validated if there is no unacceptable use error.

  2. Validation of usability (2) [2 hours]

    Task completion rate: percentage of use scenarios completed without observation of an unacceptable error. The unacceptable nature of an error is determined according to the risk analysis process covered by ISO 14971:2019. Validated if the success rate on each task must reach 78% at minimum.

  3. Validation of no safety critical of use [2 hours]

    Safety critical error: a user error that causes a safety incident, where safety is defined as the appearance of a hazardous situation and the related harms linked to an unacceptable risk, as stated in the application version of Risk Analysis. Validated if there is no safety critical error has been identified during the evaluation.

  4. Validation of ease of use [2 hours]

    The MuCopilot solution will be considered as easy to use, if the perceived ease of use" mean score reaches 7.8/10

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Aged ⩾ 18 years old

  • Patients diagnosed with cystic fibrosis

  • Enrolled in or benefiting of a Social Security program

  • Having read the information sheet and signed the informed consent form

  • Owning a personal smartphone which version is above 14 for IOS and 8 for Android included with a good internet connexion

  • Able to read French and understand pictograms on a smartphone app

Exclusion Criteria:
  • History of lung transplantation

  • Pregnant women and women who are breastfeeding

  • Any medical condition that could interfere with the proper conduct and results of the study (clinician's judgement)

  • Illiterate in French

  • Inability to use a smartphone or MuCopilot application

  • Person under legal protection (including guardianship or curatorship)

Contacts and Locations

Locations

Site City State Country Postal Code
1 CRCM Mixte - Hôpital Charles Nicolle Rouen France 76031

Sponsors and Collaborators

  • Ad scientiam

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ad scientiam
ClinicalTrials.gov Identifier:
NCT06132048
Other Study ID Numbers:
  • ADS-MuControl-Summative-2023
First Posted:
Nov 15, 2023
Last Update Posted:
Nov 15, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 15, 2023